Wiskott-Aldrich Syndrome Protein (WASP, encoded by the WAS gene) is a critical intracellular effector that couples Rho-family GTPases, particularly CDC42, to actin cytoskeleton remodeling via the Arp2/3 complex. Predominantly expressed in hematopoietic cells, dysregulation of WASP leads to severe primary immunodeficiencies (Wiskott-Aldrich Syndrome) or, conversely, drives metastasis and invasion in hematological and solid tumors. Developing therapeutics targeting WASP—ranging from gene therapies restoring expression to small molecules modulating its autoinhibited conformation—requires highly characterized, sequence-verified molecular tools.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for WASP/WAS drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human WASP (Full-Length & GBD/VCA Domains) High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for binding assays. |
View WASP Products |
| Gene Delivery | WASP Promise-ORF / Lentivirus Full-length ORF for stable reconstitution assays in WASP-deficient cell lines. |
View WASP Products |
| Benchmark Ab | Anti-WASP Recombinant Antibody Validated for western blot and immunoprecipitation positive controls. |
View WASP Products |
| Validator | WASP siRNA Set Target-specific knockdown verification in functional migration assays. |
View WASP Products |
| Related Target A | CDC42 Upstream Rho GTPase regulator that binds and activates WASP via the GBD domain. |
View CDC42 Products |
| Related Target B | WIPF1 (WIP) WASP-interacting protein that stabilizes WASP from degradation; key target for disruption. |
View WIPF1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Conformational Dynamics (Autoinhibition vs. Active) | Recombinant WASP GBD and VCA domains available separately with verified theoretical MW and high purity (>95%) for precise biophysical binding assays. |
| Protein Instability & Degradation in vitro | Co-expressed WASP/WIPF1 complex proteins and high-purity constructs expressed in E. coli/Insect cells to ensure conformational stability. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control expression vectors included in the portfolio. |
| Off-Target Cytoskeletal Toxicity | N-WASP (WASL) homolog panel proteins available for counter-screening to ensure WASP-specific targeting. |
Live WASP/WAS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for WASP is bifurcated. In the field of rare diseases, autologous hematopoietic stem cell gene therapy (utilizing lentiviral vectors to deliver functional WAS genes) represents the clinical vanguard, aiming to permanently cure Wiskott-Aldrich Syndrome. Concurrently, in oncology and autoimmune sectors, the focus has shifted toward small-molecule modulators. Inhibiting the interaction between WASP and its chaperone WIPF1, or blocking the CDC42-WASP binding pocket, is emerging as a powerful strategy to suppress cancer cell invasion and pathological immune cell trafficking.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (Lentiviral) | Orchard Therapeutics, Genethon | Wiskott-Aldrich Syndrome (WAS) | Transduction efficiency and functional recovery assays (Need WASP Lentivirus & Benchmark Abs) |
| Small Molecule Inhibitor | Academic Spin-offs, Biotech | Solid Tumors (Metastasis), Autoimmunity | Disruption assays of WASP-WIPF1 or WASP-CDC42 (Need high-purity recombinant domains) |
| RNA Therapeutics | Preclinical Developers | Inflammatory Diseases | Target knockdown and expression rescue validation (Need verified siRNA & qPCR controls) |